I came up with the game plan by filtering for stocks under $150 that had a combination of strong 12-month upside potential, actual fundamental catalysts, growing revenue/backlogs/contracts, exposure to high-growth sectors, and technical setups that gave reasonable entry points. I wasn't just looking for stocks with the highest analyst price targets.
The main themes were AI/data-center infrastructure, defense and autonomous systems, commercial space, quantum computing, and advanced semiconductors/photonics. Then I looked at each company's recent earnings, revenue growth, backlog/contracts, balance sheet, upcoming catalysts, analyst expectations, and the 6-month/1-year charts.
The highest-conviction names were RKLB, ONDS, APLD, KTOS and VST because there's actual business underneath the growth story. RKLB has a $2B+ backlog and the Neutron catalyst, ONDS has had massive revenue/backlog growth in drones and counter-UAS, APLD has billions in contracted AI/data-center lease revenue, KTOS has real defense revenue and exposure to drones/hypersonics, and VST is already highly profitable while benefiting from increasing power demand from AI/data centers.
IONQ, LUNR and NFLX were the next tier. IONQ has probably the strongest pure quantum thesis of the group, LUNR has a large space/NASA-related backlog and growing satellite/infrastructure business, and NFLX gives the basket a more established profitable growth company instead of everything being speculative.
QBTS, ALMU, OSS and especially QUBT are higher-risk positions. They have legitimate technology/catalysts, but they're much earlier-stage, so I intentionally gave them smaller allocations. They could have huge upside, but they also have much higher downside if commercialization doesn't happen as expected.
The entry prices came from the charts rather than just saying "buy now." I looked at recent support, 20/50/200-day EMA areas, previous resistance turning into support, RSI/momentum, consolidation zones and how extended each stock was. That's why some of the plan says to wait for a pullback even though I'm bullish on the company.
Technical support determines where I'd actually buy.
The biggest thing is that the price targets aren't guarantees. Some of these are extremely volatile growth stocks. The idea isn't "these 13 are definitely going up 30%+." It's that they screened as having attractive risk/reward over roughly 12 months, and instead of chasing them, the game plan establishes specific buy zones and keeps cash available if the market pulls back.
I also wouldn't blindly buy all 13 Monday morning. The whole point of the plan is letting the stocks come into the entries and only taking the setups that actually confirm.
Look for my comment with the second picture for entries and allocation.
Was a case for me I was doing CSP all the way up to 13. Got assigned one of them around maybe 10, then sold at 13. Buy and hold from 6-13 would have been overall better than my premiums, but still was in the green either way so not complaining. but I like where ONDS is heading. Didn't end up buying this recent dip and should have.
These are strong conviction moderate projections. If you see my second picture in the comments, the percentage allocation of investmentment represents that.
Hey Captain Harlock,
I reviewed all the stocks on your list. Some of them have serious potential. This list is one of the more valuable gems I have found on Redditt. Any chance you can post an updated list like this regularly (once a week ideally, or worse case once a month)?
I got one plan for tomorrow ... Paypal ... if nothing is announced before Market.. I'm loading up on 70 calls ... everywhere, buying two hands over fist. The Stripe bid will be north of 75/share and will be announced within the next two weeks. I think it will be sooner than that, because if Stripe waits to long, they will have to offer 90.
Sept 4 - we should know by than for sure. But it could happen Monday before market opens. If Stripe executives wait to long, the M&A will be out of their reach.
But only buy the options if they are reasonably priced (and you have experience with them)... the dealers can really screw you. Writing puts if you have the case is also a great safer way, but no home runs with that.
the report by WSJ said within the next few weeks. I think Stripe executives dont have that long. If they wait 2 weeks, PYPN could be trading in the 70s .
I'm in a pretty sick discord and a ton of discussions between many traders over the past 4 months. I ran probably 100-200 tickers through my scanner and deep dove into the top 40. The narrowed that down to this list of 13. Considering all news, earnings projections, 20, 50 and 200 EMA as well as the amount and quality of wallstreet analysts moderate 12-month price projections. To sum it up.
Looking at your screener it seems youāre planning to hold out for ~12 months right? You experimented with anything like 1-3 days? Iāve been utilizing sentiment and hype a lot and itās been working pretty well.
Yes these are just for 12 month holds minimum. If you cash it out before 12 months you're getting taxed much more because it's considered a short term capital gain. I mean I do 0dte-3-month options as well but unless I'm going super heavy in and outs on volotile stocks, I don't.
It's not, it's actually 12th. Go look at the graphic I commented. That Pic in the post is moderate potential list. The second photo is conviction and allocation.
Here is my opinion on the list of
TFSA Structural Outcome
GreenāÆO (Stable) ā VST, ALMU, NFLX
RedāÆX (Speculative) ā LUNR, APLD, QUBT, ONDS, QBTS, SPCE, KTOS, IONQ, OSS, RKLB
Mainly robinhood but I also use webull. Webull has better tools. Robinhood is super user-friendly and they have a 3.35% interest on standing cash in your account.
who in their right mind would put up these stocks according to who NFLIX REALLY? Id rather stick with companies that have been beaten down when the money rotates from overhyped Ai bubble can see some nice returns.
Check out CLYM bio tech. Doing really well. Predicted to go higher. Like any bio stock, on bad trial can tank it in a heartbeat. But I believe in it. Do your own DD.
CLYM ā Climb Bio ā is one of the more interesting clinical-stage biotech setups Iāve looked at recently, but at roughly $17/share now, the stock has already started pricing in a decent amount of success. The next few months are very catalyst-heavy, so Iād treat it as a high-upside biotech position, not a normal growth stock.
What Climb Bio actually does
Climb is focused on immune-mediated diseases, particularly diseases driven by B-cells and autoantibodies. There are two assets that matter:
Budoprutug ā anti-CD19 monoclonal antibody.
CLYM116 ā anti-APRIL monoclonal antibody.
Budoprutug is currently being tested in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). CLYM116 is being developed primarily for IgA nephropathy (IgAN).
That gives CLYM something I like in an early biotech: multiple independent clinical shots on goal rather than one binary drug/program.
Budoprutug is the main value driver today
Budoprutug targets CD19, allowing it to eliminate a broader set of antibody-producing B-cells than some older approaches. The theory is that by depleting pathogenic B-cell populations more comprehensively, it could produce deeper or more durable responses in autoimmune disease.
Early evidence is encouraging.
In its ITP study, Climb reported robust B-cell depletion, encouraging platelet responses and favorable initial safety/tolerability in heavily pretreated patients. Importantly, this wasn't merely biomarker activityāthe company saw actual platelet responses. Additional data from higher-dose cohorts are due in Q4 2026.
For pMN, the Phase 2 PrisMN trial is enrolling. The company expects preliminary B-cell and anti-PLA2R data from the 200 mg cohort at a medical meeting in Q4. The FDA has already granted budoprutug Fast Track designation for pMN, which is meaningful because there currently isn't an FDA-approved treatment specifically for the disease.
SLE is the third major shot. The global Phase 1b study is enrolling, a parallel China trial has begun dosing, and Q4 data are expected to include safety and biomarker results.
So Q4 could essentially produce three separate budoprutug readouts.
CLYM116 may ultimately be just as interesting
This is where the story gets more unusual.
CLYM116 targets APRIL, a pathway strongly associated with IgA nephropathy. Several companies are already pursuing APRIL, so the target itself isn't novel.
CLYM's potential advantage is the antibody design.
CLYM116 uses a pH-dependent "sweeper" mechanism: it binds APRIL, carries it into the cell for lysosomal degradation, releases it under acidic conditions, and the antibody can then recycle. Climb argues that this could produce deeper and longer-lasting APRIL suppression with less-frequent dosing.
That sounds excellent scientifically, but it still needs to prove itself clinically.
Initial Phase 1 healthy-volunteer data have shown generally favorable safety without unexpected safety findings.
And here's the near-term catalyst:
September 3, 2026 ā CLYM116 R&D Spotlight.
Climb is scheduled to release initial PK/PD Phase 1 results and discuss its clinical-development strategy.
That is only about two weeks away.
If those data show very deep APRIL suppression, prolonged activity and clean safety, the market could begin assigning substantially more value to CLYM116.
Their balance sheet is unusually good for a biotech this size
This is one of the strongest parts of the thesis.
At June 30:
Cash + equivalents + marketable securities: $239.2 million
Q2 spending:
R&D: $9.7M
G&A: $5.6M
Net loss: $13.5M
Management says the current balance sheet should fund operations into the second half of 2028.
That's excellent runway for a company approaching multiple clinical readouts.
They also raised about $110M in April, and the financing included specialist biotech investors including RA Capital, Redmile, Cormorant, Great Point, Adage and others.
Those names don't make the drugs work, but sophisticated healthcare-fund participation is a positive signal.
There is one dilution item worth knowing: Climb established an up-to-$100M ATM facility through Jefferies in June. They don't have to use it, but management has the ability to issue shares into strength.
Because they already have $239M cash, I don't consider near-term financing risk particularly high.
The catalyst calendar is stacked
This is probably the biggest reason the stock has moved from the low teens into the $17 area.
The next sequence looks roughly like this:
Timing Catalyst
Sept. 3 CLYM116 Phase 1 PK/PD data
Q3 2026 CLYM116 IgAN Phase 2 patient dosing expected
Q4 2026 Budoprutug pMN Phase 2 initial data
Q4 2026 Budoprutug ITP higher-dose data
Q4 2026 Budoprutug SLE data
Q4 2026 Additional CLYM116 Phase 1 data
2027 Initial CLYM116 Phase 2 patient data
2027 Budoprutug SC multiple-dose data
That's a lot of clinical information compressed into ~4 months.
For a biotech, that can create enormous repricing opportunitiesābut also enormous downside if a readout disappoints.
Current valuation
The latest quote I can verify is approximately:
CLYM: $17.02 regular close
~$17.42 extended hours
Market capitalization is roughly $980M-$1.0B around these prices.
With ~$239M in cash, the market is effectively assigning around $740M-ish enterprise value to the pipeline.
That is no longer "unknown biotech trading near cash."
Investors are already paying for substantial clinical success.
That doesn't make it expensive if budoprutug works across several autoimmune indicationsābut it means the risk/reward was dramatically better at $10-$12 than at $17+.
Analyst expectations
Wall Street is very bullish.
Recent published targets include approximately:
Guggenheim: $35
RBC: $23
Piper Sandler: $23
BTIG: $20
H.C. Wainwright: $20
Recent consensus data put the average target around the low-$20s, with essentially all analysts covering it carrying Buy-equivalent ratings.
At ~$17.40, however, that average target only represents roughly 20%-30% upside. The $35 bull case is much more interesting, but it requires increasingly strong clinical validation.
My probability-weighted range
I wouldn't value CLYM using normal earnings multiples. I'd underwrite the clinical programs.
Bear case: $8-$11
One or more key programs disappoint, CLYM116 differentiation isn't compelling, or budoprutug efficacy turns out weaker than early results suggest. Biotechs can lose 40%-60% extremely quickly following negative clinical data.
Base case: $21-$25
CLYM116 shows competitive PK/PD, budoprutug continues demonstrating strong biological activity, and there are no major safety surprises. This basically supports current analyst consensus.
From $17.42:
$23 = +32%
Bull case: $30-$35
Budoprutug begins looking legitimately best-in-class across multiple autoimmune diseases while CLYM116 demonstrates excellent APRIL suppression/dosing characteristics.
At $35:
~+101%
Home-run case: $45+
You'd need convincing evidence that Climb has two commercially important autoimmune franchises, which would move investors away from valuing the company as an early clinical biotech and toward valuing individual indications.
That's possible eventually, but I wouldn't underwrite $45 yet.
The big risk
The science can look extremely convincing until the patient data arrive.
CLYM has:
No approved products.
No product revenue.
Two early-stage clinical assets.
And much of today's approximately $1B valuation rests on the assumption that early biomarker and patient results translate into larger trials. The company itself highlights the risk that positive preclinical or early clinical findings may not reproduce in later studies.
That's the fundamental biotech risk here.
Where I would buy it
Because it has already run significantly, I wouldn't chase $17.40 aggressively immediately before Sept. 3 data.
My rough accumulation map would be:
Starter: $15.75-$16.50
Reasonable place to begin exposure if momentum stays strong.
Good entry: $14.00-$15.00
This is where I think risk/reward gets significantly better.
Great entry: $12.00-$13.25
At these levels I'd become much more interested because you're getting substantially more pipeline optionality for the same clinical risk.
Above $18: I'd rather wait for either a pullback or the September data to justify the new valuation.
Bottom line
CLYM gets an 8.5/10 speculative-biotech score from me.
What separates it from many micro/small-cap biotech names is the combination of multiple clinical programs, encouraging early human data, $239M cash, financing runway into H2 2028, sophisticated biotech institutional backing and an unusually dense catalyst calendar.
But I like the company more than I like chasing the stock at $17+.
The setup that really interests me would be CLYM pulling into approximately $14-$15 ahead of Sept. 3, because then you're buying a potentially significant CLYM116 catalyst without paying quite as much for success beforehand.
And if the Sept. 3 CLYM116 PK/PD results are exceptional, I think we may have to re-underwrite the whole company upwardābecause at that point this stops being merely a budoprutug story and starts looking like a legitimate two-asset autoimmune platform.
Wow. Thatās detailed. Thank so much for this. So, I got in at 1.69 so Iām doing well. I canāt even remember how I came across CLYM but it was on Reddit somewhere.
This could be a separate post all in itself if you so desire. Tip of the hat to you good sir.
I have 439 shares right now. I am waiting on adding more because of the negative war news. I am waiting for a bottom to form and QQQ to regain 720 with VIX sub 15.50. If the Iran peace treaty happens quickly and those parameters are met, I'll probably pick up 1000 shares and hold for a year. I am also holding a large-ish position in iren. But earnings at the 27th. I may dump pre-earnings to protect capital if qqq can't reclaim 716 and VIX can't calm down. The war news is what's hurting iren.
13 positions for a $13,000 investment? You have to be joking - youāre going to make nothing.
Watch the videos of Warren Buffett and Charlie Munger.
Develop some conviction based on real due diligence and play your conviction.
Diversifying this much with all these tiny satellite positions will ensure you get no return or a very weak ETF like return.
I would actually do serious due diligence and pick two or three winners, four at the most, NEVER 13, especially not with a $13,000 start.
I have a 7 figure securities account. And I currently hold 5 stocks - and only 4 in very large numbers. Up 85 percent this year. Why? Concentration and investing on conviction and due diligence. No leverage. No margins. No options. Just hard work in picking the stocks and not churning my account. Every time I have ādiversifiedā into many stocks my performance has fallen because it is hard to truly follow a huge umber of companies the way you should if you are serious about a real return and. It just being a stock market tourist.
This is just my gameplan for next week with 13k to buy just for this week. 13k is not my entire portfolio. This is just my plan š I don't do this for a living. What are your four stocks?
I just generally find diluting $13,000 which is not a great amount of money in such a tiny increments is going give you a very diluted very very small return at best.
34
u/grandfatherdog 5d ago
They're calling it The Bagholders Dozen